Mage-a4 tcr
This open-label, phase 1 trial was conducted at multiple centers in North America to evaluate the safety of afami-cel in HLA … See more Patients who were HLA-A*02:05+ in either allele, those with HLA-A*02:07 as the sole HLA-A*02 allele and those with any A*02 null allele (designated with an ‘N’; for example, A*02:32N) … See more Patients must have voluntarily agreed to participate by giving written informed consent in accordance with International Council on Harmonization (ICH) Good Clinical Practice (GCP) guidelines and applicable local … See more The sample size for this study was not pre-specified. This phase 1 study was not statistically powered to evaluate either safety or efficacy; … See more WebMay 25, 2024 · A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA …
Mage-a4 tcr
Did you know?
WebMay 29, 2024 · The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in … WebJun 29, 2024 · The MAGE-A4 antigen was expressed in 54.9% of oesophageal cancers, 37.5% of head and neck cancers, 35.0% of gastric cancers and 34.2% of ovarian cancers; …
WebAug 26, 2024 · 第四代TCR-T是靶向肿瘤新抗原（neoantigen）的高特异性细胞疗法，肿瘤应答和安全性大幅提高。 据不完全统计，全球约有50多款在研TCR-T疗法，主要针对转移性非小细胞肺癌、肝细胞癌、多发性骨髓瘤、软组织肉瘤、头颈癌、黑色素瘤等适应症。 其中tebentafusp进展最快，目前处于上市申请阶段。 此外，今年6月Adaptimmune公司宣布 …
WebMar 30, 2024 · 专门采用针对MAGE-A4癌症抗原的TCR-T技术 afamitresgene autoleucel（afami-cel，以前称为ADP-A2M4），在多种实体瘤类型，包括滑膜肉瘤、头部肿瘤、宫颈癌和肺癌中均获得了缓解，并且多名患者出现持久反应，这意味着这种新型的基于TCR的新兴技术是未来攻破实体瘤的新 ... WebAn anti-MAGE-A4 CTL clone was obtained and the epitope was found to be decapeptide GVYDGREHTV (amino acids 230-239) presented by HLA-A2 molecules. The CTL clone …
WebNov 24, 2024 · Here, we describe this strategy using a developmental T-cell therapy, ADP-A2M4, which recognizes the HLA-A2-restricted MAGE-A4 peptide GVYDGREHTV. ADP-A2M4 demonstrated potent anti-tumor activity in the absence of major off-target cross-reactivity against a range of human primary cells and cell lines.
WebOct 15, 2024 · Coexpression of the MAGE-A4 TCR and CD8α in CD4 + T-cells in the patient MP enabled CD4 + T-cells to kill tumor target cells directly in vitro. MAGE-A4 expression in tumor biopsies varied... dj setup imagesWebMar 15, 2024 · The co-expression of MAGE-A4 and MAGE-A10 in several tumors suggests that future research should focus on co-targeting multiple MAGE-A antigens (Figure 3 B). … dj setup kaufenWebMAGE-A4是在多种实体瘤公认的好靶点，香雪生命科学在多年前已经做了布局，已经研发了多款靶向MAGE-A4 TCR-T产品，而且香雪生命科学更关注于更适用于中国人群TCR-T产品。 联合CD8分子使得MAGE-A4 TCR-T如虎添翼，多快好省的调用更多T细胞。 香雪也有这样的管线布局，同时也在评估其他分子的协同作用。 多年的磨砺，宝剑出鞘的刹那光芒万丈 … dj setup images hdWebMar 15, 2024 · MZ2-E (now known as MAGE-A1), the first cancer/testis antigen, was discovered nearly 31 years ago in 1991. It was discovered via the recognition of a melanoma cell line in vitro by autologous cytotoxic CD8 T cells. MAGE-A1 emerged as an antigen presented on the cell surface by the major histocompatibility complex (MHC) [9]. dj setup imageWebJul 25, 2024 · 靶向MAGE-A4/ HLA-A24:02的临床试验没有得到那么明显的结果：输注的T细胞能够维持长达五个月的时间，但没有观察到客观响应，毒副作用也很小。 关注非自身抗原 最近，以人乳头瘤病毒（HPV）抗原为代表的非自身抗原靶向的TCR成为新的研究点。 目前NCI的Christian Hinrichs正在进行一项关于HPV E6 TCR免疫疗法的临床试验，该疗法用于 … dj setup photoWebMay 14, 2015 · Using MAGE-A4 peptide/HLA-A*24:02 tetramer, the frequencies of MAGE-A4 TCR–positive T cells were analyzed by flow cytometry. MAGE-A4-tetramer + /CD8 + T … dj setup ipadWebJan 1, 2002 · MAGE-A4 is a germ cell-specific marker which is expressed differentially in testicular tumor and it is a potential target for immunotherapy [145, 146]. scRNAseq data … dj setup learn